Cohen's newer venture, the precision-medicine biotech MENTSH Therapeutics, carries the work forward, and in April 2025 he joined the scientific advisory board of Niagen Bioscience (the NAD+ company formerly known as ChromaDex), whose CEO Rob Fried described the appointment as a chance to "learn from one of the great minds in mitochondrial and longevity research."14 The lesson for buyers: promising biology and a durable product are different things, and the gap between them is where a lot of money and hope get lost
Dose: 500 mg Role: Exercise-Mimetic Signaling Fat Browning & Fatty Acid Oxidation
Chen, D.Y
Common side effects (rare): Temporary fatigue in first 3-5 days Mild headaches Injection site redness Increased appetite Vivid dreams (uncommon) Serious side effects (very rare): Allergic reaction to peptide Injection site infection (poor technique) Dizziness or lightheadedness Who shouldn't use BPC-157: Pregnant or breastfeeding women Active cancer diagnosis (promotes angiogenesis) Recent retinal surgery (blood vessel growth in eye) Known allergy to peptides Drug interactions: BPC-157 doesn't interact with most medications, but combining with: NSAIDs: BPC-157 protects against NSAID damage (actually beneficial) Blood thinners: Monitor closely due to angiogenesis effects Immunosuppressants: May reduce BPC-157 effectiveness Dosing mistakes to avoid Get the protocol right from the start
Data availability The datasets generated and analyzed during this study are included in the Supplementary files
The peptide appears to enhance fibroblast recruitment, stimulate collagen deposition, and promote re-epithelialization through activation of the ERK1/2 signaling cascade
